Cell Therapy Catapult to work with GSK on Cell Therapies
Complete the form below to unlock access to ALL audio articles.
The Cell Therapy Catapult, which is focused on the development of the UK cell therapy industry to increase the nation’s health and wealth, will be working with GlaxoSmithKline plc (GSK) to explore potential collaborations in a range of areas relevant to the development of cell therapies, from research projects to technical and regulatory strategy.
The Cell Therapy Catapult is a centre of excellence for cell therapy and regenerative medicine established in 2012 to stimulate innovation in this area. Its staff are experts in cell therapy, from clinical and regulatory strategy to process development, scale-up and business development, and are focused on sharing their insight across the cell therapy sector in the UK. GSK is currently developing a bone marrow-derived stem cell gene therapy through late phase development and has a small number of collaborations in this field.
Keith Thompson, CEO of the Cell Therapy Catapult, said: ‘As it is a leading player in the global pharmaceutical industry and a strong supporter of UK science and innovation, it is very pleasing that our first ‘big pharma’ partnership is with GlaxoSmithKline. We look forward to sharing expertise and working together, an interaction which we expect to add significant value to the UK cell therapy industry.’
Jan Thirkettle, Head of Advanced Therapy Delivery at GSK, said: ‘We are pleased to be working with the Cell Therapy Catapult which is well placed to facilitate development of best practice and build a skills base which we believe will be critical to the progression of this new and technically challenging field.’
